GUSTO cost-effectiveness analysis sets new standard for integrating cost in clinical trials -- NEJM editorial.
Executive Summary
GUSTO COST-EFFECTIVENESS ANALYSIS SETS NEW STANDARD FOR CLINICAL TRIALS to include cost outcomes in drug development, Thomas Lee, MD, Brigham & Women's Hospital, asserted in an editorial accompanying an article on the cost of the thrombolytic agent in the May 25 issue of the New England Journal of Medicine. "In important ways, this article sets a new standard for the integration of cost-effectiveness research into randomized trials," Lee maintained.